Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 3,135 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo solution Clear all
Completed Phase 3 Interventional Results available

Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation

NCT03248037
View directory record Official record
Conditions
Fuchs' Endothelial Dystrophy, Bullous Keratopathy
Interventions
Netarsudil, Placebo
Drug
Lead sponsor
Cornea Research Foundation of America
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 12, 2021 · Synced Oct 17, 2026, 6:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Intra-operative Ketamine Infusions in Opioid-dependent Patients With Chronic Lower Back Pain

NCT00899600
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Ketamine, Normal saline
Drug · Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 17, 2026, 6:50 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Intranasal Oxytocin Intervention for Caregivers to Persons With Dementia

NCT06364228
View directory record Official record
Conditions
Stress
Interventions
Placebo, Oxytocin Intranasal Spray 12 International Unit (12IU), Oxytocin Intranasal Spray 24 International Unit (24IU), Functional MRI
Drug · Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
50 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 17, 2026, 6:50 PM EDT
Completed Phase 2 Interventional Results available

CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)

NCT02617667
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Cyclosporine A, Placebo
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years to 99 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Newport Beach, California • Lewiston, Maine • Andover, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Oct 17, 2026, 6:50 PM EDT
Completed Phase 1 Interventional

Tolerability, Safety and Efficacy of RKI983 Eye Drops in Subjects With Primary Open Angle Glaucoma and Ocular Hypertension

NCT00515424
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
RKI983
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Timeline
Started 2007
U.S. locations
5
States / cities
Artesia, California • Rochester, New York • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 17, 2026, 6:50 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep

NCT02856594
View directory record Official record
Conditions
Postoperative Delirium, Sleep, Anesthesia
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years and older
Enrollment
469 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 17, 2026, 6:50 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Vitamin B12 Treatment in Singers

NCT03437824
View directory record Official record
Conditions
Vitamin B 12 Deficiency
Interventions
Cyanocobalamin, Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 17, 2026, 6:50 PM EDT
Completed Phase 2 Interventional Results available

Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes

NCT00791479
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2189265 and Lifestyle Measures, Placebo solution and Lifestyle Measures
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
12
States / cities
Concord, California • Lancaster, California • Mission Hills, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Oct 17, 2026, 6:50 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy

NCT01475786
View directory record Official record
Conditions
Painful Diabetic Neuropathies
Interventions
Low Dose: 16 mg Engensis (VM202), High Dose: 32 mg Engensis (VM202), Control- Placebo (normal saline)
Biological · Other
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Walnut Creek, California • Orlando, Florida • Palm Beach Gardens, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 17, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability and Pharmacokinetic Study of CPP-115

NCT01493596
View directory record Official record
Conditions
Cocaine Dependency
Interventions
CPP-115, Placebo
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 17, 2026, 6:50 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Trial of Oxytocin Alone Versus Oxytocin and Propranolol for the Treatment of Abnormal Labor

NCT00315913
View directory record Official record
Conditions
Dysfunctional Labor
Interventions
Propranolol, IV Placebo
Drug · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 17, 2026, 6:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis

NCT01533480
View directory record Official record
Conditions
Keratoconjunctivitis Due to Adenovirus, Viral Shedding
Interventions
Zirgan, genteal gel
Drug
Lead sponsor
Lifelong Vision Foundation
Other
Eligibility
14 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 17, 2026, 6:50 PM EDT
Completed Phase 3 Interventional Results available

Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%

NCT03519386
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
G2-TR intraocular implant containing travoprost, Sham surgery + active-comparator eye drops
Combination Product · Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 17, 2026, 6:50 PM EDT
Completed Phase 3 Interventional Results available

MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis

NCT01180634
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Aeroquin, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
95
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 17, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers

NCT02066909
View directory record Official record
Conditions
Healthy
Interventions
0.15 mg PF-06649751, 0.5 mg PF-06649751, 1.5 mg PF-06649751, 1.5 mg PF-06649751 21 Days, 3.0 mg PF-06649751, 5.0 mg PF-06649751, 8.0 mg PF-06649751, 1.5 mg PF-06649751 in healthy Japanese subjects
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Oct 17, 2026, 6:50 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

RCT of Progesterone to Prevent Preterm Birth in Nulliparous Women With a Short Cervix

NCT00439374
View directory record Official record
Conditions
Preterm Delivery, Cervical Length
Interventions
17 alpha-hydroxyprogesterone caproate, Placebo Oil
Drug · Other
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
657 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
14
States / cities
Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 17, 2026, 6:50 PM EDT
Active, not recruiting Phase 3 Interventional

Study of OT-101 in Treating Myopia

NCT04770610
View directory record Official record
Conditions
Myopia, Progressive
Interventions
OT-101 Ophthalmic Solution, Vehicle
Drug
Lead sponsor
Ocumension (Hong Kong) Limited
Other
Eligibility
3 Years to 15 Years
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
15
States / cities
Colorado Springs, Colorado • Fort Collins, Colorado • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 17, 2026, 6:50 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes

NCT01681290
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
CBX129801
Drug
Lead sponsor
Cebix Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
22
States / cities
Escondido, California • Fresno, California • Irvine, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2015 · Synced Oct 17, 2026, 6:50 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

HAT for the Treatment of Sepsis Associated With NASTI

NCT05157360
View directory record Official record
Conditions
Necrotizing Soft Tissue Infection, Sepsis
Interventions
HAT, Placebo
Drug
Lead sponsor
Ascension Health
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 17, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.

NCT00463320
View directory record Official record
Conditions
Macular Degeneration, Age-related Macular Degeneration
Interventions
Pazopanib eye drops and Allergen Refresh Plus eye drops
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
2
States / cities
Fargo, North Dakota • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 17, 2026, 6:50 PM EDT
Terminated Phase 4 Interventional Results available

Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery

NCT03824808
View directory record Official record
Conditions
Kidney Cancer, Prostate Cancer
Interventions
Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution, 0.9% Sodium Chloride Injection
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 17, 2026, 6:50 PM EDT
Terminated Phase 2 Interventional Results available

Tranexamic Acid and Thromboelastography During Cesarean Delivery

NCT02026297
View directory record Official record
Conditions
Postpartum Hemorrhage
Interventions
Tranexamic Acid, Placebo; Normal Saline
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 17, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Results available

Lipopolysaccharide (LPS) Challenge in Depression

NCT03142919
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Lipopolysaccharide, Placebo
Biological
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 17, 2026, 6:50 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

NCT03185819
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Intranasal Placebo, Midazolam Placebo Solution, Midazolam, Esketamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
9 Years to 17 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
18
States / cities
Hartford, Connecticut • New Haven, Connecticut • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 17, 2026, 6:50 PM EDT